A total of 19 products were added in the month from 12 different asset managers: ACRE Advisors, Amundi, Archimed, Bice, BlackRock, Eastspring, Invesco, iShares, MGG Investment Group, Stellex Capital, Stone Harbor and VanEck.
ETF listings approved by the CCR reach 875 products
Asset managers are expanding their ETF footprint in anticipation of asset allocation shifts driven by Chile’s pension reform, positioning themselves for the transition to a generational fund structure.
CCR Monthly Approval Report – January 2026
Sponsors gaining approval were Amundi, Azimut, Blue Owl Capital, Echiquier, Eurazeo, Invesco, iShares, Leonard Green and M&G.
CCR Monthly Approval Report – December 2025
Bradesco, HSBC, Invesco, VanEck, Wisdomtree, Lone Star Funds and TPG Angelo Gordon were the fund sponsors gaining approval for new product.
CCR Monthly Approval Report – November 2025
Alpheon, Danske, DPAM, Fidelity, Global X, iShares, Sixth Street, T. Rowe Price and Wellington were the fund sponsors gaining approval for new products in November.
CCR Monthly Approval Report – October 2025
Xtrackers got 37 of its ETFs registered in the month, while UBS had one equity mutual fund approved.
CCR Monthly Approval Report – September 2025
DWS, Vanguard, WisdomTree, Bci, T. Rowe Price, CapVest, Inflexion PE Partners and WindRose Health Investors were the managers registering products in September 2025.
CCR Monthly Approval Report – August 2025
Aberdeen, Azimut, BlueBay, Franklin Templeton, GHO Capital, InfraRed CP, Invesco, iShares, JP Morgan, Stone Harbor and Vinci Partners were the fund sponsors gaining approval for new products in August.
CCR Monthly Approval Report – July 2025
A total of 14 products were added in the month from seven different asset managers: Greenbriar, Franklin Templeton, LBPAM, Niam AB., Morgan Stanley, Pictet and UBAM.
CCR Monthly Approval Report – June 2025
In June, Allianz, iShares, Jupiter, Lord Abbett, Vontobel, Wellington, Energy Capital Partners, Pemberton AM, and Ridgemont Equity Partners were the fund sponsors gaining approval for new products.


